Synplogen Signs Partner Marketing Agreement with Ginkgo Bioworks

Synplogen Co., Ltd. (Head office: Chuo-ku, Kobe; Representative Director and CEO: Kazuhiko Yamamoto; hereinafter referred to as "Synplogen"), a biotech startup spun out of Kobe University, has signed Partner Marketing Agreement with Ginkgo Bioworks (hereinafter referred to as "Ginkgo").

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, provides flexible and consistent platform services to solve customer challenges in a wide variety of markets, including food, agriculture, pharmaceuticals, and specialty chemicals.

KBIC hosted “Regenerative Medicine Industrialization Forum 2024 in Nihonbashi” on January 26th and attracted industry and academia in the field of Cell and Gene Therapy

On January 26th, KBIC hosted "Regenerative Medicine Industrialization Forum 2024 in Nihonbashi" together with City of Kobe, IQVIA Services Japan Ltd. and Life Science Innovation Network Japan (Link-J) in Tokyo. This event aims to share common issues and challenges among companies, research institutions and academia, promoting mutual collaboration to accelerate industrialization of Regenerative Medicine field. On the day of event, approximately 750 people (onsite + online) attended and learned about the latest developments in the area of cell and gene therapy.